A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis
Therasphere consists of glass microspheres containing a radioactive material called
Yttrium-90.
Therasphere is delivered into the liver tumor through a catheter placed into the hepatic
artery which is the artery that provides the main blood supply to the tumor, this way
delivering the radioactive material directly to the tumor and sparing the rest of the liver
tissue from radiation.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate to the administration of Therasphere
Participants will be followed through 1 year after the procedure at 1 month, 3 months, 6 months and 1 year visits
No
Hyun s Kim, MD
Principal Investigator
Emory University
United States: Institutional Review Board
00015167
NCT01556282
March 2009
December 2017
Name | Location |
---|---|
Emory University Hospital | Atlanta, Georgia 30322 |